Compare · MDWD vs RLX
MDWD vs RLX
Side-by-side comparison of MediWound Ltd. (MDWD) and RLX Technology Inc. (RLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDWD and RLX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $2.09B, about 13.3x MDWD ($157.6M).
- MDWD has hit the wire 1 time in the past 4 weeks while RLX has been quiet.
- MDWD has more recent analyst coverage (8 ratings vs 2 for RLX).
- Company
- MediWound Ltd.
- RLX Technology Inc.
- Price
- -
- -
- Market cap
- $157.6M
- $2.09B
- 1M return
- -
- -1.16%
- 1Y return
- -
- -29.31%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- 2021
- News (4w)
- 1
- 0
- Recent ratings
- 8
- 2
MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
Latest MDWD
- MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
- Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
- Director Rubinstein Samuel sold $6,678 worth of Ordinary Shares (525 units at $12.72) and bought $6,626 worth of Ordinary Shares (525 units at $12.62) (SEC Form 4)
- MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- COO & Chief Commercial Officer Hess Shmuel sold $75,394 worth of Ordinary Shares (5,823 units at $12.95), closing all direct ownership in the company (SEC Form 4)
- SEC Form 6-K filed by MediWound Ltd.
- MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- MediWound to Report Second Quarter 2026 Financial Results
- Director Shamir Nachum bought $83,996 worth of Ordinary Shares (6,000 units at $14.00), increasing direct ownership by 12% to 55,815 units (SEC Form 4)
- Director Fox David Morton bought $49,901 worth of Ordinary Shares (3,537 units at $14.11), increasing direct ownership by 19% to 22,283 units (SEC Form 4)
Latest RLX
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited Second Quarter 2026 Financial Results
- RLX Technology to Report Second Quarter 2026 Financial Results on August 14, 2026
- SEC Form 4 filed by Chief Financial Officer Lu Chao
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited First Quarter 2026 Financial Results
- RLX Technology to Report First Quarter 2026 Financial Results on May 20, 2026
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate